On August 1, 2019 Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, reported that Bob Azelby, Alder’s president and chief executive officer, will provide a business overview and update at the Canaccord Genuity 39th Annual Growth Conference at 12:30 p.m. ET on Thursday, August 8, 2019 in Boston, MA (Press release, Alder Biopharmaceuticals, AUG 1, 2019, View Source [SID1234538034]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live on the Events & Presentations page of the Investors section of Alder’s website at View Source, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder’s website for at least 30 days after the live event concludes.

On August 1, 2019 Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, reported it will report its second quarter 2019 financial results and business progress on Thursday, August 8, 2019, after the close of the U.S. financial markets (Press release, Tocagen, AUG 1, 2019, View Source [SID1234538050]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To receive Tocagen’s press releases and other investor information, please visit the Investor Relations page of the company’s website and register for email alerts.

On August 1, 2019 Bracco Imaging reported that it has completed the acquisition of Blue Earth Diagnostics, a molecular imaging company based in Oxford, UK, from leading healthcare company Syncona Ltd. and Blue Earth Diagnostics’ management team (Press release, Blue Earth Diagnostics, AUG 1, 2019, View Source [SID1234538079]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Blue Earth Diagnostics is now officially a subsidiary of Bracco Imaging, led by its current leadership team and will retain the well-established Blue Earth Diagnostics name, and HQ in Oxford, UK, while maintaining a significant and operational presence across the US, based in Boston, Massachutes.

"We are thrilled to officially welcome to Bracco this world-class team with exceptional product development and commercialization expertise." said Fulvio Renoldi Bracco, Chief Executive Officer, Bracco Imaging. "Our new relationship will enable both companies to realize their full potential by significantly broadening our combined portfolio in precision medicine and personalized diagnostics, while expanding our range of nuclear oncology imaging solutions in the Urology segment and other specialties."

"Now begins the next stage in our adventure, as Blue Earth Diagnostics, a Bracco company,", said Jonathan Allis, Chief Executive Officer at Blue Earth Diagnostics, "I am certain that it will be an exciting and meaningful one. We have the opportunity to work together with a world’s leading company in the diagnostic imaging business, to advance research and provide products that can make a meaningful difference in even more patients’ lives than ever before."

Blue Earth Diagnostics employs approximately 100 people and is expected to generate revenues of $140M in the year to September 2019, primarily in the US.

Copy of the Bracco press release announcement acquisition and other corporate information can be found at: View Source

On August 1, 2019 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the "Company") reported that it will release its second quarter 2019 financial results on Tuesday, August 6, 2019, after the market closes (Press release, Aurinia Pharmaceuticals, AUG 1, 2019, View Source [SID1234538003]). Aurinia’s management team will host a conference call to discuss the company’s financial results and to provide a general business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call and webcast is scheduled for August 6, 2019 at 4:30pm ET. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

On August 1, 2019 Spectrum Pharmaceuticals (NasdaqGS: SPPI), reported it will host a conference call with management to discuss the second quarter 2019 financial results, provide an update on the company’s business, and discuss expectations for the future on Thursday, August 8, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific (Press release, Spectrum Pharmaceuticals, AUG 1, 2019, View Source [SID1234538019]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call:

Thursday, August 8, 2019 @ 4:30 p.m. Eastern/1:30 p.m. Pacific

Domestic: (877) 837-3910, Conference ID# 5378656

International: (973) 796-5077, Conference ID# 5378656

For interested individuals unable to join the call, a replay will be available from August 8, 2019 @ 7:30 p.m. ET/4:30 p.m. PT through August 15, 2019 until 11:59 p.m. ET/8:59 p.m. PT.

Domestic Replay Dial-In #: (855) 859-2056, Conference ID# 5378656

International Replay Dial-In #: (404) 537-3406, Conference ID# 5378656

This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals’ website: View Source on August 8, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.